Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 Dec;67(12):6335-40.
doi: 10.1128/IAI.67.12.6335-6340.1999.

Expression of sialylated or paragloboside-like lipooligosaccharides are not required for pustule formation by Haemophilus ducreyi in human volunteers

Affiliations

Expression of sialylated or paragloboside-like lipooligosaccharides are not required for pustule formation by Haemophilus ducreyi in human volunteers

R S Young et al. Infect Immun. 1999 Dec.

Abstract

The lipooligosaccharide (LOS) of Haemophilus ducreyi, the etiologic agent of chancroid, chemically and immunologically resembles human glycosphingolipid antigens. To test whether LOS that contains paragloboside-like structures was required for pustule formation, an isogenic mutant (35000HP-RSM2) was constructed in losB, which encodes D-glycero-D-manno-heptosyltransferase. 35000HP-RSM2 produces a truncated LOS whose major glycoform terminates in a single glucose attached to a heptose trisaccharide core and 2-keto-3-deoxyoctulosonic acid. Five human subjects were inoculated with 35000HP and 35000HP-RSM2 in a dose-response trial. For estimated delivered doses (EDDs) of >/=25 CFU, the pustule formation rates were 80% for 35000HP and 58% for 35000HP-RSM2. Preliminary data indicated that a previously described Tn916 losB mutant made a minor glycoform that does not require DD-heptose to form the terminal N-acetyllactosamine. If 35000HP-RSM2 made this glycoform, then 35000HP-RSM2 could theoretically make a sialylated glycoform. To test whether sialylated LOS was required for pustule formation, a second trial comparing an isogenic sialyltransferase mutant (35000HP-RSM203) to 35000HP was performed in five additional subjects. For EDDs of >/=25 CFU, the pustule formation rates were 30% for both 35000HP and 35000HP-RSM203. The histopathology and recovery rates of H. ducreyi from surface cultures and biopsies obtained from mutant and parent sites in both trials were similar. These results indicate that neither the expression of a major glycoform resembling paragloboside nor sialylated LOS is required for pustule formation by H. ducreyi in humans.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Silver stain of an SDS–16% PAGE gel of LOS preparations from the parent and mutant strains of H. ducreyi. Lane 1, LOS from strain 35000HP; lane 2, LOS from the sialyltransferase mutant 35000HP-RSM203; lane 3, LOS from the dd-heptosyltransferase mutant 35000HP-RSM2. The sialic acid-containing glycoform in the parent strain is designated by the arrow.
FIG. 2
FIG. 2
Hematoxylin-eosin-stained sections (×25) obtained from sites inoculated with 35000HP (A), 35000HP-RSM2 (B), 35000HP (C), and 35000HP-RSM203 (D). Tissues shown in panels A and B were obtained from subject 88, and those in panels C and D were from subject 119. Note that all specimens contain subepidermal or intraepidermal pustules.

Similar articles

Cited by

References

    1. Al-Tawfiq, J., J. Harezlak, B. P. Katz, and S. M. Spinola. Cumulative experience with Haemophilus ducreyi in the human model of experimental infection. Sexually Trans. Dis., in press. - PubMed
    1. Al-Tawfiq J A, Thornton A C, Katz B P, Fortney K R, Todd K D, Hood A F, Spinola S M. Standardization of the experimental model of Haemophilus ducreyiinfection in human subjects. J Infect Dis. 1998;178:1684–1687. - PubMed
    1. Al-Tawfiq, J. A., M. E. Bauer, K. R. Fortney, B. P. Katz, A. F. Hood, M. Ketterer, M. A. Apicella, and S. M. Spinola. Submitted for publication.
    1. Al-Tawfiq, J. A., K. R. Fortney, B. P. Katz, C. Elkins, and S. M. Spinola. Submitted for publication.
    1. Bauer B A, Lumbley S R, Hansen E J. Characterization of a waaF (RfaF) homolog expressed by Haemophilus ducreyi. Infect Immun. 1999;67:899–907. - PMC - PubMed

Publication types

LinkOut - more resources